EXICURE, INC. Variable Lease, Cost
EXICURE, INC. (XCUR) reported Variable Lease, Cost of $87.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-03-25
- EXICURE, INC. variable lease, cost for the quarter ending 2023-03-31 was $332.00K, a 2.64% decline year-over-year.
- EXICURE, INC. variable lease, cost for the quarter ending 2022-12-31 was $342.00K, a 28.09% increase year-over-year.
- EXICURE, INC. variable lease, cost for the quarter ending 2022-09-30 was $341.00K, a 47.62% increase year-over-year.
- EXICURE, INC. variable lease, cost for the quarter ending 2022-06-30 was $505.00K, a 158.97% increase year-over-year.
- EXICURE, INC. variable lease, cost for fiscal 2025 was $87.00K, a 70.00% decline from fiscal 2024.
- EXICURE, INC. variable lease, cost for fiscal 2024 was $290.00K, a 57.97% decline from fiscal 2023.
- EXICURE, INC. variable lease, cost for fiscal 2023 was $690.00K, a 54.87% decline from fiscal 2022.
- EXICURE, INC. variable lease, cost for fiscal 2022 was $1.53M, a 42.90% increase from fiscal 2021.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $87.00K 10-K · filed 2026-03-25 | |||
| 2024-12-31 | $290.00K 10-K · filed 2026-03-25 | |||
| 2023-12-31 | $690.00K 10-K · filed 2025-03-18 | |||
| 2023-03-31 | $332.00K 10-Q/A · filed 2024-06-06 | $674.00K derived: sum of 2 quarters · filed 2024-06-06 | $1.01M derived: sum of 3 quarters · filed 2024-06-06 | $1.52M derived: sum of 4 quarters · filed 2024-06-06 |
| 2022-12-31 | $342.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-06-06 | $683.00K derived: sum of 2 quarters · filed 2024-06-06 | $1.19M derived: sum of 3 quarters · filed 2024-06-06 | $1.53M 10-K · filed 2024-06-06 |
| 2022-09-30 | $341.00K 10-Q · filed 2022-11-14 | $846.00K derived: sum of 2 quarters · filed 2022-11-14 | $1.19M 10-Q · filed 2022-11-14 | $1.45M derived: sum of 4 quarters · filed 2024-06-06 |
| 2022-06-30 | $505.00K 10-Q · filed 2022-08-15 | $846.00K 10-Q · filed 2022-08-15 | $1.11M derived: sum of 3 quarters · filed 2024-06-06 | $1.34M derived: sum of 4 quarters · filed 2024-06-06 |
| 2022-03-31 | $341.00K 10-Q/A · filed 2024-06-06 | $608.00K derived: sum of 2 quarters · filed 2024-06-06 | $839.00K derived: sum of 3 quarters · filed 2024-06-06 | $1.03M derived: sum of 4 quarters · filed 2024-06-06 |
| 2021-12-31 | $267.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | $498.00K derived: sum of 2 quarters · filed 2023-03-27 | $693.00K derived: sum of 3 quarters · filed 2023-03-27 | $1.07M 10-K · filed 2023-03-27 |
| 2021-09-30 | $231.00K 10-Q · filed 2022-11-14 | $426.00K derived: sum of 2 quarters · filed 2022-11-14 | $803.00K 10-Q · filed 2022-11-14 | $1.00M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $195.00K 10-Q · filed 2022-08-15 | $572.00K 10-Q · filed 2022-08-15 | $771.00K derived: sum of 3 quarters · filed 2022-08-15 | $943.00K derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $377.00K 10-Q · filed 2022-05-16 | $576.00K derived: sum of 2 quarters · filed 2022-05-16 | $748.00K derived: sum of 3 quarters · filed 2022-05-16 | $840.00K derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $199.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-25 | $371.00K derived: sum of 2 quarters · filed 2022-03-25 | $463.00K derived: sum of 3 quarters · filed 2022-03-25 | $521.00K 10-K · filed 2022-03-25 |
| 2020-09-30 | $172.00K 10-Q · filed 2021-11-19 | $264.00K derived: sum of 2 quarters · filed 2021-11-19 | $322.00K 10-Q · filed 2021-11-19 | $406.00K derived: sum of 4 quarters · filed 2021-11-19 |
| 2020-06-30 | $92.00K 10-Q · filed 2021-08-12 | $149.00K 10-Q · filed 2021-08-12 | $234.00K derived: sum of 3 quarters · filed 2021-08-12 | $318.00K derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $57.00K 10-Q · filed 2021-05-12 | $142.00K derived: sum of 2 quarters · filed 2021-05-12 | $226.00K derived: sum of 3 quarters · filed 2021-05-12 | $317.00K derived: sum of 4 quarters · filed 2021-05-12 |
| 2019-12-31 | $85.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $169.00K derived: sum of 2 quarters · filed 2021-03-11 | $260.00K derived: sum of 3 quarters · filed 2021-03-11 | $344.00K 10-K · filed 2021-03-11 |
| 2019-09-30 | $84.00K 10-Q · filed 2020-11-12 | $175.00K derived: sum of 2 quarters · filed 2020-11-12 | $259.00K 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $91.00K 10-Q · filed 2019-08-08 | $175.00K 10-Q · filed 2019-08-08 | ||
| 2019-03-31 | $84.00K 10-Q · filed 2020-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |